Fampridine STADA: Uses, Dosage & Side Effects
A potassium channel blocker used to improve walking ability in adult patients with multiple sclerosis who have walking disability
Fampridine STADA is a prescription medication containing fampridine (also known as 4-aminopyridine or dalfampridine), a potassium channel blocker specifically indicated to improve walking ability in adult patients with multiple sclerosis (MS) who have walking disability, defined as an Expanded Disability Status Scale (EDSS) score of 4 to 7. Fampridine works by blocking voltage-gated potassium channels on demyelinated nerve fibers, thereby enhancing nerve signal conduction along damaged axons. It is taken as a 10 mg prolonged-release tablet twice daily, exactly 12 hours apart. Clinical trials have shown that approximately 35–43% of patients experience a clinically meaningful improvement in walking speed, as measured by the Timed 25-Foot Walk test. Fampridine STADA is a generic formulation bioequivalent to the originator product Fampyra.
Quick Facts: Fampridine STADA
Key Takeaways
- Fampridine STADA is a generic prolonged-release tablet containing fampridine 10 mg, bioequivalent to Fampyra, used to improve walking in adult MS patients with an EDSS score of 4–7.
- The medication works by blocking potassium channels on demyelinated nerve fibers, restoring more efficient nerve signal conduction and improving walking speed in approximately 35–43% of patients (known as “responders”).
- Take exactly one 10 mg tablet every 12 hours — never exceed two tablets per day. Tablets must be swallowed whole, never crushed or split, as this increases seizure risk due to rapid drug release.
- The most serious risk is seizures, especially at higher doses or in patients with impaired kidney function. Fampridine is contraindicated in patients with a history of seizures or moderate-to-severe renal impairment.
- Walking ability should be assessed after a 2-week trial period; if no improvement is observed, treatment should be discontinued as further benefit is unlikely.
What Is Fampridine STADA and What Is It Used For?
Fampridine STADA contains the active substance fampridine, also known by its chemical name 4-aminopyridine (4-AP) and marketed in the United States as dalfampridine (brand name Ampyra). Fampridine is a broad-spectrum potassium channel blocker that has been specifically developed as a prolonged-release (extended-release) oral formulation for the symptomatic treatment of walking disability in adult patients with multiple sclerosis. Fampridine STADA is a generic formulation manufactured by STADA Arzneimittel AG that has demonstrated bioequivalence to the originator product Fampyra (manufactured by Biogen), meaning it delivers the same amount of active substance to the bloodstream at the same rate.
Multiple sclerosis is a chronic autoimmune disease of the central nervous system in which the body's immune system attacks the myelin sheath — the protective insulating layer that surrounds nerve fibers (axons) in the brain and spinal cord. This process, known as demyelination, disrupts the normal conduction of electrical signals along nerve fibers. When myelin is damaged, voltage-gated potassium channels that are normally concealed beneath the myelin sheath become exposed on the surface of the axon. Potassium ions leak out through these exposed channels, causing the nerve impulse (action potential) to dissipate prematurely and fail to reach its intended target. This disruption of nerve conduction is responsible for many of the neurological symptoms experienced by MS patients, including weakness, fatigue, difficulty walking, and impaired coordination.
Fampridine works by blocking these exposed voltage-gated potassium channels on demyelinated axons. By preventing the outward leakage of potassium ions, fampridine prolongs the duration of the action potential and enhances the amplitude of the nerve signal as it travels along the damaged nerve fiber. This improved conduction translates into more effective communication between nerve cells and the muscles they control, which can result in measurably improved walking ability. The mechanism is selective for demyelinated fibers because normally myelinated nerves have their potassium channels hidden beneath intact myelin and are therefore unaffected by fampridine at therapeutic concentrations.
The efficacy of fampridine in improving walking speed in MS patients has been established in two pivotal phase III randomized, double-blind, placebo-controlled trials (MS-F203 and MS-F204) and confirmed by the subsequent European extension study (ENHANCE). In these trials, patients treated with fampridine prolonged-release 10 mg twice daily were assessed using the Timed 25-Foot Walk (T25FW), a standardized measure of walking speed. The primary endpoint was the proportion of patients classified as “timed walk responders” — defined as patients who showed a consistent improvement in walking speed during the treatment period compared to their non-treatment visits.
- MS-F203 Trial: In this 14-week study of 301 patients, 34.8% of patients on fampridine were classified as responders compared with 8.3% on placebo (p < 0.001). Responders had a mean improvement in walking speed of approximately 25.2%.
- MS-F204 Trial: In this 9-week study of 239 patients, 42.9% of fampridine-treated patients were responders compared with 9.3% on placebo (p < 0.001). Again, the mean improvement in walking speed among responders was approximately 24.7%.
- ENHANCE Trial: This European study of 636 patients over 24 weeks confirmed the findings of the pivotal trials, with 43.2% of fampridine-treated patients meeting the responder criteria compared with 33.6% on placebo using the revised response criteria. This trial also demonstrated improvements in the 12-item MS Walking Scale (MSWS-12), a patient-reported outcome measure of walking ability and quality of life.
An important characteristic of fampridine treatment is the concept of “responders” versus “non-responders.” Not all patients benefit from fampridine; the drug produces a clinically meaningful improvement in walking speed in approximately one-third to two-fifths of treated patients. Those who respond typically do so within the first 2–4 weeks of treatment. Current clinical guidelines therefore recommend an initial trial period of 2 weeks, after which walking ability should be objectively assessed. If no improvement is observed, treatment should be discontinued. For patients who do respond, the benefits are often sustained over long-term treatment, as demonstrated in open-label extension studies lasting up to 5 years.
Fampridine was first approved by the FDA in January 2010 (as Ampyra) and by the EMA in July 2011 (as Fampyra). It is approved in more than 50 countries worldwide. Fampridine STADA, as a generic formulation, provides the same clinical benefits at a potentially lower cost, improving access for MS patients who could benefit from this symptomatic treatment.
Fampridine does not work for all MS patients with walking difficulty. Approximately 35–43% of patients experience a meaningful improvement in walking speed. Your doctor will assess your walking ability before and after a 2-week trial period. If you are a responder, you are likely to notice that walking feels easier, faster, or less fatiguing. If no improvement occurs within 2 weeks, treatment will be stopped, as further benefit is unlikely.
What Should You Know Before Taking Fampridine STADA?
Contraindications
Fampridine STADA must not be used in the following situations:
- History of seizures: Fampridine lowers the seizure threshold in a dose-dependent manner. Patients with any history of seizure activity, including febrile seizures in childhood, must not take this medication. Seizures are the most serious adverse effect associated with fampridine and can occur even at the recommended dose, though the risk increases substantially at higher doses.
- Moderate or severe renal impairment: Because fampridine is eliminated primarily through the kidneys (approximately 90% excreted unchanged), reduced kidney function leads to elevated plasma concentrations and a significantly increased risk of seizures. Patients with a creatinine clearance below 80 mL/min must not use fampridine. Kidney function must be assessed before initiating treatment.
- Concomitant use of other fampridine-containing products: Patients must not take Fampridine STADA together with any other medication containing fampridine or 4-aminopyridine, including compounded formulations, as this would result in overdosing and increased seizure risk.
- Hypersensitivity: Do not use if you are allergic to fampridine (4-aminopyridine) or any of the excipients in the tablet formulation, including hypromellose, microcrystalline cellulose, colloidal anhydrous silica, magnesium stearate, and the film-coating components.
Warnings and Precautions
Fampridine can cause seizures. The risk increases with higher plasma levels due to overdose, renal impairment, or interactions. If a seizure occurs, stop taking fampridine immediately and seek emergency medical attention. Do not restart treatment. Never take more than one 10 mg tablet every 12 hours.
Before starting Fampridine STADA, discuss the following with your healthcare provider:
- Kidney function: Your doctor must check your kidney function (creatinine clearance) before starting fampridine and should recheck it at least annually during treatment. Even mild changes in kidney function can significantly increase fampridine levels in the blood. If your kidney function declines during treatment, your doctor may need to discontinue fampridine.
- Cardiac arrhythmias: Fampridine has been associated with QT prolongation in some pharmacological studies, although clinical trials at the recommended dose did not demonstrate clinically relevant effects on cardiac rhythm. Patients with a history of cardiac arrhythmia, long QT syndrome, or those taking other QT-prolonging medications should be monitored more closely.
- Infections: Urinary tract infections (UTIs) are more commonly reported in patients taking fampridine. MS patients may already be prone to UTIs due to bladder dysfunction, and fampridine may increase this risk. Report symptoms of UTI (burning sensation during urination, frequent urination, fever) to your doctor promptly.
- Dizziness and balance: Fampridine may cause dizziness and balance disturbance, which could increase the risk of falls. This is particularly relevant for MS patients who already have impaired mobility and balance. Use caution when walking or performing activities that require coordination, particularly during the initial weeks of treatment.
- Trigeminal neuralgia: Cases of trigeminal neuralgia (severe facial pain) have been reported during post-marketing experience. If you develop new onset of severe facial pain, inform your healthcare provider.
Pregnancy and Breastfeeding
There are limited data on the use of fampridine in pregnant women. Animal studies have shown reproductive toxicity at doses considerably higher than the recommended human dose, including reduced offspring survival and growth retardation. As a precaution, fampridine should not be used during pregnancy unless the potential benefit clearly outweighs the potential risk to the fetus. Women of childbearing potential should use effective contraception during treatment.
It is not known whether fampridine is excreted in human breast milk. Given the small molecular size of fampridine (molecular weight 94 g/mol), excretion into breast milk is likely. A risk to the breastfed infant cannot be excluded, particularly given the potential for neurological effects. The decision to continue or discontinue breastfeeding or fampridine treatment must be made in consultation with your healthcare provider, weighing the benefit of breastfeeding against the benefit of fampridine treatment for the mother.
Children and Adolescents
Fampridine STADA is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of fampridine have not been established in this age group. MS in children is rare and may require different therapeutic approaches tailored to the pediatric population.
Elderly Patients
Clinical trials of fampridine did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. Since kidney function naturally declines with age, elderly patients are more likely to have reduced renal clearance, which increases the risk of elevated fampridine levels and seizures. Kidney function should be carefully assessed before initiating treatment in elderly patients and monitored regularly throughout treatment.
How Does Fampridine STADA Interact with Other Drugs?
Fampridine is a small molecule (molecular weight 94 g/mol) that is primarily eliminated unchanged through the kidneys via a combination of glomerular filtration and active tubular secretion. Approximately 90% of an administered dose is excreted unchanged in the urine. The active tubular secretion of fampridine is mediated by the organic cation transporter 2 (OCT2) in the renal tubules. Fampridine undergoes minimal hepatic metabolism, and the cytochrome P450 (CYP) enzyme system plays only a minor role in its clearance. As a result, pharmacokinetic interactions with CYP-metabolized drugs are not expected.
However, there are several important interaction considerations:
| Drug / Category | Interaction Type | Clinical Significance | Recommendation |
|---|---|---|---|
| Cimetidine | OCT2 inhibition — increases fampridine levels | Major | Concomitant use not recommended |
| Other OCT2 inhibitors (e.g. carvedilol, propafenone, quinidine) | OCT2 inhibition — may increase fampridine levels | Moderate | Use with caution; monitor for side effects |
| Other fampridine / 4-AP products | Additive dose — increased seizure risk | Major (Contraindicated) | Must not be combined |
| Baclofen | Pharmacodynamic — both affect CNS excitability | Minor | May be used together; increased fall risk possible |
| Drugs lowering seizure threshold (e.g. tramadol, bupropion, chlorpromazine) | Pharmacodynamic — additive seizure risk | Moderate | Use with caution; weigh risks carefully |
| MS disease-modifying therapies (interferons, glatiramer, natalizumab, fingolimod, dimethyl fumarate, ocrelizumab) | No pharmacokinetic interaction | None identified | Can be used together safely |
Major Interactions
The most clinically relevant drug interaction involves cimetidine, a histamine H2-receptor antagonist used for acid reflux, which is also a potent inhibitor of the OCT2 transporter. In a pharmacokinetic study, concomitant administration of cimetidine 400 mg with fampridine led to an increase in fampridine exposure (AUC) of approximately 22%. While this may seem modest, because fampridine has a narrow therapeutic window and seizure risk increases in a dose-dependent manner, even small increases in plasma levels can be clinically significant. Concomitant use of fampridine with cimetidine is therefore not recommended.
Concurrent use of any other products containing fampridine or 4-aminopyridine is absolutely contraindicated. In some countries, compounded immediate-release 4-aminopyridine formulations have been available through specialty pharmacies. Patients must ensure they are not taking any additional source of fampridine while on Fampridine STADA.
Minor Interactions
Fampridine can be safely combined with most MS disease-modifying therapies, including interferon beta-1a, interferon beta-1b, glatiramer acetate, natalizumab, fingolimod, dimethyl fumarate, teriflunomide, cladribine, and ocrelizumab. Population pharmacokinetic analyses from clinical trials have confirmed the absence of clinically significant interactions with these agents. Symptomatic medications commonly used in MS, such as modafinil for fatigue, gabapentin for neuropathic pain, and oxybutynin for bladder symptoms, have also not shown significant interactions with fampridine.
Always inform your doctor and pharmacist about all medicines, supplements, and herbal products you are taking. While fampridine has few drug interactions, its narrow therapeutic window means that even small changes in blood levels can affect safety. If you are prescribed a new medication, check with your healthcare provider or pharmacist whether it may affect fampridine levels or seizure risk.
What Is the Correct Dosage of Fampridine STADA?
Fampridine STADA has a fixed-dose regimen with no dose titration. The prolonged-release formulation is specifically designed to deliver the active substance at a controlled rate, reducing peak plasma concentrations and minimizing the risk of dose-dependent seizures that were historically seen with immediate-release 4-aminopyridine formulations.
Adults
Standard Adult Dose
Dose: 10 mg (one tablet) every 12 hours
Maximum daily dose: 20 mg (two tablets) per 24 hours
Administration: Oral, with or without food
Important: Swallow tablets whole. Do not split, crush, chew, or dissolve.
The 12-hour dosing interval is critical for maintaining consistent plasma levels and minimizing the risk of adverse effects. Patients should take the medication at approximately the same times each day (for example, 8:00 AM and 8:00 PM) to maintain this interval. Taking two doses too close together increases peak plasma concentrations and raises seizure risk.
Fampridine can be taken with or without food. While food slightly delays the time to peak plasma concentration (Tmax) by approximately 1 hour, it does not significantly affect the overall extent of absorption (AUC) or the clinical efficacy of the drug. Patients may therefore take the medication according to their own meal schedule.
| Patient Group | Dose | Frequency | Special Considerations |
|---|---|---|---|
| Adults (18–64 years) | 10 mg | Every 12 hours | Check kidney function before starting |
| Elderly (≥65 years) | 10 mg | Every 12 hours | Mandatory kidney function check; monitor closely for adverse effects |
| Mild renal impairment (CrCl ≥80 mL/min) | 10 mg | Every 12 hours | Standard dose; monitor kidney function regularly |
| Moderate/severe renal impairment (CrCl <80 mL/min) | Contraindicated | — | Do not use — increased seizure risk |
| Children and adolescents (<18 years) | Not recommended | — | Safety and efficacy not established |
Missed Dose
If you forget to take a dose at the scheduled time, do not take a double dose to make up for the missed one. Taking two tablets close together can cause dangerously elevated blood levels and increase the risk of seizures. If you remember the missed dose within a few hours, take it and then adjust your schedule to maintain the 12-hour interval. If it is nearly time for your next dose, skip the missed dose entirely and resume your regular schedule.
Overdose
Fampridine overdose is a medical emergency. Symptoms may include confusion, tremor, excessive sweating, and seizures. Seizures have been reported at doses as low as 15 mg taken as a single dose. If overdose is suspected, seek emergency medical attention immediately. There is no specific antidote; treatment is supportive, including seizure management with benzodiazepines.
In clinical trials and post-marketing experience, adverse neurological events (including seizures) have been observed at doses higher than the recommended 10 mg twice daily. The dose-response relationship for seizure risk is steep: while the incidence of seizures at the recommended dose is approximately 0.4%, the risk increases markedly with even modest dose increases. At 15–20 mg per single dose, seizure risk increases substantially. Fampridine overdose may also cause other symptoms of central nervous system excitation, including confusion, tremor, diaphoresis (excessive sweating), memory impairment, and in severe cases, status epilepticus.
In the event of suspected overdose, the patient should be taken to the emergency department immediately. Management is supportive and symptomatic: intravenous benzodiazepines (such as diazepam or lorazepam) are the first-line treatment for fampridine-induced seizures. There is no specific antidote. Because fampridine has relatively low protein binding, hemodialysis may be considered in severe overdose situations, although clinical data on its effectiveness are limited.
What Are the Side Effects of Fampridine STADA?
Like all medicines, Fampridine STADA can cause side effects, although not everybody gets them. The side effect profile of fampridine has been well characterized through clinical trials involving over 1,200 MS patients and extensive post-marketing surveillance since its approval in 2010. Most side effects are mild to moderate in severity and are often difficult to distinguish from MS symptoms themselves. Below is a comprehensive overview of side effects organized by frequency according to European regulatory convention.
Very Common
- Urinary tract infection (approximately 12% of patients)
Common
- Insomnia (difficulty sleeping)
- Dizziness
- Headache
- Balance disorder
- Paraesthesia (tingling, numbness, or “pins and needles”)
- Tremor
- Nausea
- Vomiting
- Constipation
- Back pain
- Asthenia (general weakness or lack of energy)
Uncommon
- Seizures (convulsions)
- Palpitations
- Dyspepsia (indigestion)
- Pharyngolaryngeal pain (sore throat)
- Anxiety
- Dyspnoea (shortness of breath)
- Skin rash
- Urticaria (hives)
Rare
- Anaphylaxis (severe allergic reaction)
- Angioedema (swelling of face, lips, or throat)
- Trigeminal neuralgia (severe facial nerve pain)
- Status epilepticus (prolonged seizure)
The most clinically significant adverse effect of fampridine is seizures. The seizure risk is dose-dependent, with the incidence at the recommended dose of 10 mg twice daily being approximately 0.4% (about 1 in 250 patients). Risk factors for seizures include doses exceeding the recommended 10 mg twice daily, impaired renal function (which leads to elevated plasma levels), concomitant use of OCT2 inhibitors, and a prior history of seizure activity. If a seizure occurs during fampridine treatment, the drug must be permanently discontinued.
Urinary tract infections are the most frequently reported side effect. This may be partly attributable to the underlying MS population, as bladder dysfunction is common in MS and predisposes to UTIs. However, the higher incidence in fampridine-treated patients compared to placebo in clinical trials suggests a drug-related contribution, possibly through effects on bladder smooth muscle or urinary flow patterns.
Neurological side effects such as dizziness, balance disorder, and paraesthesia are common and may overlap with MS symptoms. Patients and healthcare providers should be aware that new or worsening neurological symptoms during fampridine treatment may be drug-related rather than representing MS disease progression. If these symptoms are troublesome or persistent, a temporary discontinuation of fampridine can help clarify whether they are drug-related.
Insomnia is a commonly reported side effect that may be related to the CNS-stimulant properties of fampridine as a potassium channel blocker. Some patients find that taking the evening dose earlier (while still maintaining the 12-hour interval) can help mitigate sleep disturbance. Taking the evening dose with food may also help by slightly reducing peak plasma concentrations.
Stop taking Fampridine STADA and seek emergency medical help immediately if you experience: a seizure (convulsion); signs of a severe allergic reaction (difficulty breathing, swelling of face, lips, tongue, or throat, severe skin rash or hives); or sudden severe facial pain (possible trigeminal neuralgia). Do not restart the medication without consulting your doctor.
How Should You Store Fampridine STADA?
Proper storage of Fampridine STADA is important to maintain the integrity and effectiveness of the prolonged-release formulation. The controlled-release mechanism relies on the intact tablet structure, and exposure to excessive moisture or heat can compromise the film coating and alter drug release characteristics.
- Temperature: Store below 25°C (77°F). Do not refrigerate or freeze. Brief excursions up to 30°C (86°F) are permissible during transport but should be avoided during routine storage.
- Moisture protection: Keep the tablets in the original blister packaging until immediately before use. The blister packaging provides essential moisture protection for the prolonged-release tablet. Do not transfer tablets to a pill box or other container for extended periods.
- Light protection: Store in the original outer carton to protect from light.
- Child safety: Keep all medicines out of the sight and reach of children. Fampridine can cause seizures even in small doses and poses a particular danger to children.
- Expiry date: Do not use this medicine after the expiry date stated on the blister and outer carton. The expiry date refers to the last day of that month.
- Disposal: Do not throw away medicines via household waste or wastewater. Ask your pharmacist about the proper disposal of medicines you no longer use. This helps to protect the environment.
If you notice any visible changes to the tablets (such as discoloration, crumbling, or an unusual odor), do not take them and consult your pharmacist. Damaged prolonged-release tablets may release fampridine too quickly, potentially leading to dangerously elevated blood levels.
What Does Fampridine STADA Contain?
Understanding the composition of your medication can help you identify potential allergens and understand how the tablet is designed to work.
Active Substance
Each prolonged-release tablet contains 10 mg of fampridine (also known as 4-aminopyridine, molecular formula C5H6N2, molecular weight 94.11 g/mol). Fampridine is a white to off-white crystalline powder that is freely soluble in water. The prolonged-release formulation is designed to deliver the drug at a controlled rate over approximately 12 hours, which reduces peak plasma concentrations compared to immediate-release formulations and thereby lowers the risk of seizures.
Excipients
The inactive ingredients in Fampridine STADA prolonged-release tablets include:
- Tablet core: Hypromellose (hydroxypropyl methylcellulose — forms the prolonged-release matrix), microcrystalline cellulose (structural agent), colloidal anhydrous silica (flow agent), magnesium stearate (lubricant).
- Film coating: Hypromellose, titanium dioxide (E171 — white colorant), macrogol (polyethylene glycol — plasticizer).
The prolonged-release properties of the tablet are achieved primarily through the hypromellose matrix. When the tablet comes into contact with fluid in the gastrointestinal tract, the hypromellose swells to form a gel layer that gradually releases fampridine over an extended period. This is why it is essential to swallow the tablet whole: crushing, splitting, or chewing destroys the matrix and causes the entire 10 mg dose to be released rapidly (a phenomenon known as “dose dumping”), which significantly increases the risk of seizures and other adverse effects.
Fampridine STADA tablets are white to off-white, oval-shaped, biconvex, film-coated tablets. They do not contain lactose, gluten, sucrose, or any animal-derived ingredients.
Frequently Asked Questions About Fampridine STADA
Fampridine STADA is used to improve walking ability in adult patients with multiple sclerosis (MS) who have walking disability, typically defined as an Expanded Disability Status Scale (EDSS) score between 4 and 7. It works by blocking potassium channels on demyelinated nerve fibers, improving nerve signal conduction. Approximately 35–43% of patients experience a clinically meaningful improvement in walking speed.
Take one 10 mg tablet every 12 hours (twice daily), with or without food. Swallow the tablet whole — do not split, crush, chew, or dissolve it. The 12-hour interval is critical: taking doses too close together increases the risk of seizures. Set a consistent daily schedule (for example, 8 AM and 8 PM) to help maintain the correct interval.
The most common side effects include urinary tract infections (affecting about 12% of patients), insomnia, dizziness, headache, nausea, weakness, back pain, balance problems, and tingling sensations (paraesthesia). Most of these are mild to moderate. The most serious potential side effect is seizures, which are uncommon at the recommended dose but can occur, especially if the dose is exceeded or kidney function is impaired.
You should not take Fampridine STADA if you have a history of seizures (epilepsy or any prior convulsion), moderate or severe kidney impairment (creatinine clearance below 80 mL/min), if you are allergic to fampridine or any of the tablet ingredients, or if you are already taking another product containing fampridine or 4-aminopyridine. Your doctor must test your kidney function before prescribing this medication.
The effect on walking speed can typically be assessed within 2 to 4 weeks. Clinical guidelines recommend an initial 2-week trial, after which your doctor will evaluate your walking ability. If no improvement is observed, treatment should be stopped. Patients who respond usually notice improvements within the first few weeks, and benefits are typically sustained with continued treatment.
Yes, fampridine can generally be used alongside MS disease-modifying therapies such as interferons, glatiramer acetate, natalizumab, fingolimod, dimethyl fumarate, and ocrelizumab. No clinically significant interactions have been identified with these medications. However, you should avoid using fampridine with cimetidine (which can raise fampridine blood levels) and always tell your doctor about all medications you are taking.
References
This article is based on the following peer-reviewed sources and official regulatory documents. All medical claims follow the GRADE evidence framework at Evidence Level 1A where applicable.
- European Medicines Agency (EMA). Fampyra (fampridine) — Summary of Product Characteristics (SmPC). Last updated 2025. Available from: EMA — Fampyra
- U.S. Food and Drug Administration (FDA). Ampyra (dalfampridine) Extended-Release Tablets — Prescribing Information. Revised 2024.
- Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial (MS-F203). Lancet. 2009;373(9665):732–738. doi:10.1016/S0140-6736(09)60442-6
- Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis (MS-F204). Ann Neurol. 2010;68(4):494–502. doi:10.1002/ana.22240
- Hobart J, Ziemssen T, Feys P, et al. Assessment of clinically meaningful improvements in self-reported walking ability in participants with multiple sclerosis: results from the randomized, double-blind, phase III ENHANCE trial of prolonged-release fampridine. CNS Drugs. 2019;33(1):61–79. doi:10.1007/s40263-018-0586-5
- Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018;90(17):777–788. doi:10.1212/WNL.0000000000005347
- Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96–120. doi:10.1177/1352458517751049
- British National Formulary (BNF). Fampridine. National Institute for Health and Care Excellence (NICE). Available from: BNF — NICE
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List (2023). Geneva: World Health Organization; 2023.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians with specialist expertise in neurology, clinical pharmacology, and multiple sclerosis. Our editorial process adheres to international medical publishing standards, and all content is independently fact-checked against peer-reviewed literature and official regulatory documents.
iMedic Medical Editorial Team — Specialists in Neurology and Clinical Pharmacology
iMedic Medical Review Board — Independent panel following EMA, FDA, and WHO guidelines
GRADE Framework — Level 1A evidence from systematic reviews and RCTs where available
No pharmaceutical funding — All content is editorially independent with no conflicts of interest